- Gilead Sciences (GILD) stock went down -0.55% due to the U.S. Food and Drug Administration investigating reports of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies, which includes Gilead's Yescarta product.
- Gilead Sciences (GILD) stock went down last night due to the U.S. Food and Drug Administration investigating CAR T cancer therapies, including Gilead's own Tecartus and Yescarta, for potentially causing a type of white blood cell to become cancerous in patients who received the treatment.
- This article announces the launch of Amazon Q, a generative AI-powered assistant specifically designed for work, which allows customers to get fast and relevant answers to questions, generate content, and take actions informed by their organization's information repositories, code, and enterprise systems. Gilead Sciences' stock went down, but the article does not provide any information on why this happened.
- The article announces that preclinical data on HB-400, an investigational therapeutic vaccine for chronic hepatitis B developed in collaboration with Gilead Sciences, has been published in The Journal of Infectious Diseases, suggesting that HB-400 could be a potential component in achieving a functional cure for chronic hepatitis B; the reason behind Gilead Sciences' stock going down is not mentioned in the article.
- The Gilead Sciences (GILD) stock went down by -1.01% last night, and the article does not provide a specific reason as to why it went down.
- Gilead Sciences' stock (GILD) went down by -1.01% last night, and the article discusses the company's announcement of the PURPOSE 5 trial, which is the first Phase 2 clinical trial to evaluate a long-acting HIV prevention option in Europe, specifically lenacapavir, and aims to assess its persistence compared to other HIV prevention options. The stock may have gone down for various reasons unrelated to this announcement, such as overall market conditions, investor sentiment, or other external factors that impact stock prices.
- Gilead Sciences (GILD) stock went down by 1.01% due to news that Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated announced a transaction in which Ligand acquired a portion of the royalties owed to Ovid related to the potential approval and commercialization of soticlestat, a drug being studied for the treatment of rare epilepsies and seizure-related disorders.
- Gilead Sciences (GILD) stock went up by 1.62% after the company announced a 12-year partnership with Assembly Biosciences (ASMB) to advance research and development of novel antiviral therapies targeting herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). The partnership includes an upfront payment of $100 million to Assembly Bio, as well as potential future payments based on regulatory and commercial milestones.
- Gilead Sciences (GILD) stock went up by 1.62% due to the company's significant investment in smaller biotechnology peer Assembly Biosciences as part of a partnership to advance the research and development of novel antiviral therapies, with a focus on herpesviruses, hepatitis B virus, and hepatitis D virus. The investment includes an upfront payment of $100 million and Gilead buying nearly 13.1 million shares of Assembly at a premium price.
- The Gilead Sciences (GILD) stock went up by 1.62% last night. The article discusses the partnership between Gilead Sciences and Assembly Bio, which aims to develop next-generation antiviral therapeutics and strengthen Gilead's portfolio. The collaboration includes a cash payment and equity investment of $100 million, potentially leading to future payments for Assembly Bio. Gilead is known for its expertise in antivirals and has developed transformative medicines for viral hepatitis, including a cure for hepatitis C. The partnership will focus on developing therapies for herpesviruses and hepatitis B and D.
- Shares of Gilead Sciences (GILD) went up by 1.62% after the company agreed to a collaboration deal with Assembly Biosciences worth potentially hundreds of millions of dollars, including an upfront payment of $100 million to Assembly.
- Gilead Sciences' stock, GILD, went up by 2.0% after the company announced its participation in the 19th European AIDS Conference, where they will provide updates on HIV research, collaborations, and new scientific data, showcasing their person-centered approach to advancing scientific innovation and community partnerships to help end the HIV epidemic.
- The article announces that Fusion Pharmaceuticals has appointed Jeremy Bender, Teresa Bitetti, and David Meek to its Board of Directors, which may have contributed to the increase in Gilead Sciences (GILD) stock as Jeremy Bender, one of the appointed directors, previously served as Vice President of Corporate Development at Gilead Sciences.
- Gilead Sciences' stock (GILD) went up by 2.0% after the company presented new data supporting the use of its cancer drug, Trodelvy, in various types of metastatic cancers, including breast cancer, small cell lung cancer, urothelial cancer, and head and neck cancer.
- Gilead Sciences (GILD) stock went up by 0.57% because of a "special rebalance" of the Nasdaq 100 index, which aims to reduce the concentration of heavyweight companies that account for nearly half of the index's weight. This adjustment will result in smaller companies representing a greater percentage of the index, prompting portfolio managers to add to their positions in these companies and boost their share prices.
- The Nasdaq 100 index will undergo a "special rebalance" later this month due to the concentration of mega-cap tech stocks, with Apple and Microsoft alone representing about 25% of the index; the rebalance, which will not result in the removal or addition of any stocks, caused investors to sell mega-cap tech stocks but boosted the expectation for the stocks likely to see an increased allocation, such as Starbucks, Mondelez, Booking Holdings, Gilead Sciences, Intuitive Surgical, Analog Devices, and Automatic Data Processing.
- Gilead Sciences (GILD) stock went up because of a "special rebalance" of the Nasdaq 100 index, which aims to reduce the concentration of heavyweight companies in the index, including Microsoft, Apple, Nvidia, Amazon.com, and Tesla, that account for nearly half of its weight. The adjustment in the index's composition led to an increase in the weight of smaller companies like Gilead Sciences, which prompted portfolio managers to add to their positions, resulting in a boost in Gilead Sciences' stock price.